Elicio Therapeutics 将聚焦于R0切除人群开展3期开发,并增加Eli-2 7P给药方案

美股速递
Jun 15

Elicio Therapeutics宣布,其3期临床试验的开发策略将进一步聚焦于R0切除后的患者群体,并计划增加Eli-2 7P的给药方案。这一调整旨在更精准地评估该疗法在特定人群中的疗效与安全性,标志着公司临床开发路径的重要演进。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10